Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to treat disease. The mission of Marengo is to activate the right immune cells to promote lifelong protection against cancer. Using their understanding of T-cell receptor (TCR) biology, Marengo is designing therapies to activate a subset of T-cells known as tumor-infiltrating lymphocytes. With their versalite antibody technology platform, Marengo can modulate this subset of T-cells in different ways to support the rapid development of clinic-ready therapeutics for various diseases. Marengo’s lead candidate, START-001, is already in clinical trials for advanced antigen-rich solid tumors.

Marengo Therapeutics

Ipsen makes TCR play, grabbing two I-O therapies from Marengo - pharmaphorum

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief - Endpoints News

Shiva Bolourchi: Marengo Therapeutics is proud to be disclosing new data at AACR describing the innovative expansion of our portfolio - Oncodaily

 Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe 

Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer - PR Newswire

Join the Marengo Therapeutics team at the IO360 Summit this week - Our CEO Zhen Su, MD MBA will be giving a plenary oral presentation. Don't miss hearing first hand how we are advancing our novel T cell agonists: Zhen's session takes place on Thursday, March 26 at 2:00pm Eastern.

Check out the full agenda: https://lnkd.in/g8ZxrHHK

#IO360Summit #marengotherapeutics #immunoonology
 

 Marengo Therapeutics Appoints Elena Garralda to its Scientific Advisory Board 

 Marengo's TriSTAR technology attracts second Ipsen deal for $1.2B 

Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe - Oncodaily

Marengo closes $80M A round to harness novel antibody-mediated T-cell activation for cancer - BioWorld MedTech

 Marengo Presents Expanded Clinical Monotherapy Activity of Invikafusp Alfa in Multiple PD-1 Resistant Tumors as a Clinical Plenary Oral at AACR 2025 

Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire

Marengo Appoints Dr. Everett Vokes To Scientific Advisory Board - citybiz

This morning, Marengo Therapeutics announced that our first patient was dosed in our Phase 2 study of STAR0602, and that we have expanded the clinical study to premium oncology centers across Europe. 

Read our press release here: https://lnkd.in/gcMDAkwR
Ke Liu , MD, PhD   Zhen Su, MD MBA Kevin Chin Andrew Bayliffe ATP (Apple Tree Partners)

Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 - PR Newswire

 Marengo Therapeutics Appoints Elena Garralda, MD, PhD, to its Scientific Advisory Board 

Ipsen to Pay Marengo Therapeutics Up to $1.2 Billion Under Expanded Cancer Research Partnership - WSJ

Today, we presented expanded monotherapy activity of invikafusp alfa at AACR 2025 Clinical Plenary in PD-1 resistant tumors. The clinical presentation demonstrated the single agent pan-tumor potential and reinforced our focused expansion into mCRC and TMB-H tumors, supported by FDA Fast Track Designation.

Read the full press release: https://lnkd.in/eRZ2KivH

Marengo wants to thank all our dedicated and caring investigators. Most importantly we would like to thank our patients and their families who are our North Star.

#oncology #immunotherapy #precisionmedicine #AACR2025 #MarengoTherapeutics #Tcellactivation #biotech #CRC #NSCLC #checkpointresistance

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform - PR Newswire



			
				04/30/2025
				In the news
			

			
				Biospace: AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
			

			
				Read More
			

		

Marengo Therapeutics is proud to announce the First-in-Human preliminary clinical results of Invikafusp alfa (STAR0602), a novel Precision dual T cell agonist, will be featured as Late-breaking Oral Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston! 

We will share our learning and insights of TCR Vβ Biology from the STARt-001 trial and our proprietary bi-specific STAR™ antibody platform which is designed to reinvigorate anti-tumor T-cell responses in PD(L)1-resistant cancers.

Join us to discuss, innovate, and work toward a future where immunotherapy transforms patient outcomes. If you have not done so already you can still Register for SITC here: https://lnkd.in/ggphnMEm
#SITC2024 #Immunotherapy #CancerResearch #Innovation #Networking

Firm Advises Marengo Therapeutics on Expansion of Research Partnership with Ipsen - Wilson Sonsini

Ipsen returns to Marengo Therapeutics for new trispecific deal - Endpoints News

Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation - PR Newswire

 Tcr targeting molecules and uses thereof 


                Four from Penn elected to the National Academy of Sciences | Penn Today
              

Marengo's STAR shines as Ipsen pays $45M for 2 cancer ...

 Ipsen to Pay Marengo Therapeutics Up to $1.2B Under Expanded Cancer Research Partnership 

 Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors 

Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board - PR Newswire

Apple Tree Partners breaks into UK with biotech Adendra Therapeutics launch, $53M series A raise - Fierce Biotech

 Epstein Barr Virus Treatment Market 2034: FDA Approvals, Clinical Trials, Drugs, Medication, Companies by DelveInsight 

At Marengo Therapeutics we’re passionate about science and service, and getting our hands dirty (literally) reminds us just how connected innovation and impact can be!
For our first volunteer event of 2025 we spent the morning with The Food Project, a non-profit organization that focuses on community improvement and outreach, and education about health, leadership and sustainable agriculture. We spent the morning planting seedlings, preparing beds and greenhouses, and cleaning growing trays ahead of harvest later this year.

Huge thanks to The Food Project for letting us be part of something so “rooted” in purpose! 
We left with tired muscles, full hearts, and a whole new appreciation for where our food comes from. To learn more about The Food Project check out their website: https://lnkd.in/eTqHb4g 
#BiotechForGood #CommunityImpact #VolunteerDay #ScienceMeetsSoil

 Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board 

Join Marengo CEO, Zhen Su, MD MBA at the upcoming Longwood Healthcare Leaders Miami CEO event, April 9 - 11, where he will partake in a panel discussion on R&D Collaboration as part of Friday’s agenda.
 
 More information: https://lnkd.in/ebU5_dcQ
 
 #longwoodhealthcareleaders #ceo #biotech

 Multifunctional molecules binding to tcr and uses thereof 

Marengo's STAR shines as Ipsen hands over $45M for 2 preclinical T-cell activators - Fierce Biotech

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC - Cancer Network

Are you attending ESMO IO?  Don't miss Marengo CEO Zhen Su, MD MBA presenting Phase I clinical data on Friday, December 13, 10:30-12 noon CET.

Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe - PR Newswire

Today, March 31st, marks World Colorectal Cancer Day, and what better way to close out Colorectal Cancer (CRC) Awareness Month than with a Lunch and Learn? It was a great opportunity to come together and learn about prevention, screening, and early detection. Did you know CRC is the fourth most commonly diagnosed cancer in the U.S. and the second leading cause of cancer death? ...Yet this cancer can be prevented with screening and is highly treatable when detected early.

A big thank you to everyone at Marengo who participated and contributed to this impactful session, especially our hosts Kevin Chin and Ke Liu , MD, PhD. Let’s continue to prioritize our health and support initiatives that drive awareness and progress in the fight against colorectal cancer!

#WorldColorectalCancerDay #ColorectalCancerAwareness #LunchAndLearn #MarengoTherapeutics #CancerPrevention

Ipsen and Marengo Therapeutics announce second strategic - GlobeNewswire

Marengo Therapeutics Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune Diseases - PR Newswire

 Marengo Therapeutics Raises $80M in Funding 

Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors - PR Newswire

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation at ESMO Gastrointestinal Canc - StreetInsider

Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 - PR Newswire

 Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers 

Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutational Burden (TMB-H) - PR Newswire

Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting - PR Newswire

Last week, some of our team had the opportunity to attend the Massachusetts Conference for Women, and we couldn’t be more inspired by the impactful conversations, empowering sessions, and invaluable connections made throughout the event. Hearing from accomplished women driving innovation and excellence in their industries left us feeling motivated and ready to bring new ideas and energy to our work. The conference was a powerful reminder of the importance of collaboration and continuous learning in achieving success. A huge thank you to the organizers, speakers, and everyone who made this event a success. It was an amazing opportunity to engage with inspiring professionals, exchange ideas, and gain valuable insights to advance our efforts.

We’re excited to take these lessons and put them into action as we continue to drive progress within our team and the biotech industry.
#WomenInBusiness #Inspiration #Teamwork #Innovation #Biotech

 Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 

Marengo Presents Expanded Clinical Monotherapy Activity of Invikafusp Alfa in Multiple PD-1 Resistant Tumors as a Clinical Plenary Oral at AACR 2025 - PR Newswire

Ipsen and Marengo Expand Oncology Partnership with Next-Generation T Cell Engager Technology - The Healthcare Technology Report.

We are proud to share that Marengo will be presenting during the Clinical Plenary Oral Session at the upcoming AACR Annual Meeting - Marengo Therapeutics - Oncodaily

 Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen 

 STAT+: Up and down the ladder: The latest comings and goings 

Today James Gulley MD PhD FACP presented our Late Breaking Oral First in Human clinical data from our lead program invikafusp alfa (STAR0602) as monotherapy in PD1 resistant cancers at Society for Immunotherapy of Cancer (SITC).

To learn more details of the presentation and results read our press release:
https://lnkd.in/egvHspHu

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity - Science

 Ipsen returns to Marengo Therapeutics for new trispecific deal 

 Ipsen nominates drug candidate from Marengo partnership 

Marengo Launches to Uniquely Activate T Cells Against Cancer - BioSpace

Marengo Therapeutics Looks to Mimic 'Natural' Immune Response With T-Cell Engagers - Precision Medicine Online

Join our CEO, Zhen Su, MD MBA chair and present at the 6th TCR-based Therapies Summit on Wednesday, April 2. Marengo is thrilled to join alongside leading scientists and innovators in the field of TCR therapies to explore and drive the future of immunotherapy. Learn more about or register for the event here: https://lnkd.in/gF2zkg8
 
#Immunotherapy #Biotech #TCR #Innovation

Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers - Fierce Biotech

Marengo Announces First Patient Dosed Phase 2Clinical Study | Trending From Our Network - Chicago Star Media

 Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen 

 Ipsen nominates new drug candidate under Marengo oncology collaboration 

Biotech startup Marengo unveils $80M and a new way to get T cells to fight cancer - MedCity News

Experienced I-O researcher named CMO at Marengo - The Pharma Letter

Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

Chutes & Ladders—Moderna CFO Gomez departs after just one day following unearthed investigation - Fierce Biotech

Marengo’s TriSTAR technology attracts second Ipsen deal for $1.2B - BioWorld Online

Activating T cells to fight cancer - Nature

We are thrilled to welcome Dr. Everett Vokes to our Scientific Advisory Board! Dr. Vokes is a world-renowned thoracic oncologist, former ASCO President and Chair of the Department of Medicine at the University of Chicago. His appointment follows encouraging single-agent activity of invikafusp alfa in TMB-H solid tumors such as CRC and NSCLC. We look forward to his strategic insights as we advance our first-in-class dual T cell agonists in oncology.

Read more: https://lnkd.in/e-yjpNGB

#immunotherapy #oncology #lungcancer #biotechnews #clinicaldevelopment

First patient dosed as Marengo’s invikafusp alfa trial expands to Europe - Clinical Trials Arena

 Ipsen to Pay Marengo Therapeutics Up to $1.2 Billion Under Expanded Cancer Research Partnership 

Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy - PR Newswire

Earlier this month, our amazing team rolled up their sleeves and spent the afternoon with Community Servings, supporting their mission to provide medically tailored, nutritious, scratch-made meals to chronically and critically ill individuals and their families. It was heartwarming to see everyone come together, united by a shared purpose.
A huge thank you to Community Servings for welcoming us back to be part of this initiative for the second year in a row. We can’t wait for our next opportunity to make a positive impact!
#TeamWork #Volunteering #CommunityImpact #FoodIsMedicine

Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute - PR Newswire

ATP fuels Marengo with $80M for battle against cancers ...

We're "picking" the best talent this October: Joining the Marengo team this week is Cathy Chen and Larkin De Laria - They're the pick of the (pumpkin) patch!
 
Check out our current open roles: https://lnkd.in/eQCzHw7z

Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022 - PR Newswire

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen - PR Newswire

We are excited to share that, for the second consecutive year, Marengo Therapeutics has been certified as a Great Place to Work! 🏆
This recognition underscores our commitment to nurturing a positive, inclusive workplace where every team member is valued and empowered to succeed.
A heartfelt thank you to our exceptional team for their dedication, hard work, and passion. It is through their unwavering efforts that we have cultivated such a special workplace culture. 💼❤️
We are proud of this achievement and look forward to continuing to foster an environment where everyone can thrive.
#greatplacetowork #companyculture

 Multispecific molecules binding to tcr and uses thereof 



			
				05/08/2025
				In the news
			

			
				Marengo Begins Phase Ib/II Trial of Invikafusp Alfa, Trodelvy in Certain…
			

			
				Read More
			

		

Ipsen Invests Potential $1.6B to Turbo-Charge Marengo’s Path to the Clinic - BioSpace

Marengo has dosed the first patient in STARt-002, a Phase Ib/II trial evaluating invikafusp alfa in combination TRODELVY® (sacituzumab govitecan-hziy) HCP in metastatic breast cancer.

This milestone builds on encouraging monotherapy data in PD-1–resistant tumors and supports our strategy to advance immunotherapy-ADC combinations in broader disease settings.

We are proud to collaborate with Gilead Sciences and with leading centers including Mass General Hospital with Steven Isakofff, Sarah Cannon Research Institute with Erika Hamilton, MD, and Princess Margaret Cancer Centre with Philippe Bedard to bring new treatment options to patients.

Read Full release: https://lnkd.in/ey9jdAt6

#biotech #oncology #clinicaltrials #immunotherapy #ADC #MarengoTherapeutics #breastcancer”

Ipsen extends Marengo partnership with $1.2bn T cell research deal - Pharmaceutical Technology

 Anti-tcr antibody molecules and uses thereof 

Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer - PR Newswire

Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting - PR Newswire

 Combination therapies using molecules binding to tcr 



			
				03/28/2025
				In the news
			

			
				Precision Medicine Online: Marengo Therapeutics Looks to Mimic ‘Natural’ Immune Response…
			

			
				Read More
			

		

Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer - PR Newswire

 Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer 

Join Marengo Therapeutics CEO Zhen Su, MD MBA at the upcoming Longwood Healthcare Leaders Boston CEO event on October 28 - 29, 2024! Zhen will be speaking at the event, taking part in a panel with other industry leaders on the topic of expanding platform potential.

More information: https://lnkd.in/eehfZ2xB

#longwoodhealthcareleaders #ceo #biotech

Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine - PR Newswire

Earlier today Marengo CEO Zhen Su, MD MBA presented our clinical data at ESMO IO in Geneva, Switzerland. Many thanks to the trial patients and our clinical investigators. 

Read the press release here: https://lnkd.in/dJ5jXaqp

Marengo Therapeutics

Business:

Drug notes:

About: